Evaluation of clonal hematopoiesis and mosaic loss of Y chromosome in cardiovascular risk: An analysis in prospective studies

• Published in: eLife 2024-12, Vol.13
• Main Authors: Fawaz, Sami, Marti, Severine, Dufossee, Melody, Pucheu, Yann, Gaufroy, Astrid, Broitman, Jean, Bidet, Audrey, Soumare, Aicha, Munsch, Gaëlle, Tzourio, Christophe, Debette, Stephanie, Trégouët, David-Alexandre, James, Chloe, Mansier, Olivier, Couffinhal, Thierry
• Format: Article
• Language: English
• Subjects: Adult; Aged; Atherothrombosis; Cardiovascular Diseases - genetics; Chromosomes, Human, Y - genetics; clonal hematopoiesis; Clonal Hematopoiesis - genetics; Female; Heart Disease Risk Factors; High-Throughput Nucleotide Sequencing; Human health and pathology; Humans; inflammation; Life Sciences; Male; Medicine; Middle Aged; Mosaicism; Myocardial Infarction - epidemiology; Myocardial Infarction - genetics; Prospective Studies; Risk Factors
• ISSN: 2050-084X; 2050-084X
• DOI: 10.7554/eLife.96150

Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP. We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP. CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY. Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate